More recently, several PARP inhibitors (PARPi), including olaparib, niraparib, and rucaparib, were approved to treat ovarian cancer patients with BRCA1/2 mutations [1–4], which occur in ~20% of ovarian cancers. This evidence concerns the gene BRCA1 and ovarian carcinoma.